PrEP

Individuals who perceive themselves to be at a high risk of HIV are more likely to accept pre-exposure prophylaxis (PrEP) than their peers.

A prescription drug ad broadcast during the musical on television has set the stage for a larger conversation about patient access to preexposure prophylaxis medication.

A look at last week's top stories in the world of pharmacy.

New recommendations urge health care providers to offer pre-exposure prophylaxis (PrEP) to individuals at high risk of HIV.

Top news of the day from across the health care landscape.

Several large investigations have demonstrated the considerable efficacy of TDF/FTC taken daily or intermittently, reducing the risk of HIV acquisition by more than 95% in high-risk individuals.

The first study to evaluate population-level roll-out of pre-exposure prophylaxis (PrEP) for HIV in men who have sex with men has demonstrated rapid decline of new HIV infections.

Report analyzes HIV-related stigma among health care providers and the potential impact on quality of patient care.

An interactive text messaging intervention improves pre-exposure prophylaxis (PrEP) adherence in a study of young people at risk for HIV.

Nationwide analysis of Truvada for pre-exposure prophylaxis use finds uptake associated with significant decrease in new HIV infections.

A new study suggests that pre-exposure prophylaxis (PrEP) could also serve as a gateway to primary care services.

Top news of the day from across the health care landscape.

Despite universal access to care afforded to US military service members, there is a need to improve and expand access to PrEP for those patients at highest risk for HIV infection.

When individuals who are at risk for HIV use PrEP, and use it appropriately, risk of infection is significantly lowered.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Pre-exposure prophylaxis saves lives by reducing the risk of acquiring HIV, but the need for cost-saving is great.

Pre-exposure prophylaxis is highly effective preventing HIV if used as prescribed.

Oral preexposure prophylaxis (PrEP) has the potential to prevent HIV transmission and ultimately to help eradicate this devastating viral infection.

Findings suggest daily use of Truvada is safe and effective among males aged 15 to 17 years.

The degree of the success for HIV remission vary in different parts of the country.

Approximately 12,000 customers were affected by the breach.

Odefsey label updated to include updated data from clinical trials examining patients who switched from tenofovir disoproxil fumarate-based regimens.

Changes include additional trial data in virologically-suppressed adults with HIV-1 infection.